What is Stifel Canada’s Estimate for TSE:CPH Q1 Earnings?

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR) – Research analysts at Stifel Canada issued their Q1 2025 earnings per share (EPS) estimates for shares of Cipher Pharmaceuticals in a research report issued on Monday, March 24th. Stifel Canada analyst J. Keywood forecasts that the company will post earnings of $0.21 per share for the quarter. The consensus estimate for Cipher Pharmaceuticals’ current full-year earnings is $1.29 per share. Stifel Canada also issued estimates for Cipher Pharmaceuticals’ Q2 2025 earnings at $0.24 EPS, Q3 2025 earnings at $0.26 EPS, Q4 2025 earnings at $0.26 EPS and FY2025 earnings at $0.99 EPS.

Cipher Pharmaceuticals Price Performance

TSE CPH opened at C$12.98 on Wednesday. The company has a debt-to-equity ratio of 41.22, a quick ratio of 2.67 and a current ratio of 2.00. Cipher Pharmaceuticals has a 52-week low of C$7.90 and a 52-week high of C$19.69. The business has a 50 day simple moving average of C$12.81 and a 200 day simple moving average of C$14.33. The stock has a market cap of C$233.03 million, a price-to-earnings ratio of 14.33 and a beta of 1.20.

Insider Transactions at Cipher Pharmaceuticals

In other news, Director Harold Morton Wolkin sold 3,500 shares of the company’s stock in a transaction dated Monday, March 24th. The stock was sold at an average price of C$13.49, for a total transaction of C$47,215.00. 42.00% of the stock is owned by insiders.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, and Out-Licensed Products among others. The company’s geographical segments include Canada and the United States.